CML stands for chronic myeloid leukemia (also called chronic myelogenous leukemia).

It is a blood and bone marrow cancer in which abnormal myeloid white blood cells proliferate. Most cases are driven by the BCR::ABL1 fusion gene, usually from the Philadelphia chromosome translocation, and are treated primarily with targeted tyrosine-kinase inhibitors such as imatinib, dasatinib, nilotinib, bosutinib, asciminib, or others selected by a hematologist. The NCI CML overview summarizes diagnosis and treatment.